期刊文献+

1%卢立康唑乳膏治疗念珠菌性包皮龟头炎多中心疗效观察 被引量:7

A multicenter study on curative effect of 1% luliconazole cream in treatment of candidal balanoposthitis
下载PDF
导出
摘要 目的观察1%卢立康唑乳膏治疗念珠菌性包皮龟头炎临床疗效及安全性。方法 70例患者随机分为两组,治疗组38例,对照组32例,分别外涂1%卢立康唑乳膏与2%酮康唑乳膏,每日1次,治疗1周及2周后根据临床症状、体征及真菌学检查判定疗效,并根据不良反应评价其安全性。结果卢立康唑乳膏组1周真菌学清除率高于酮康唑乳膏组,差异有统计学意义(P<0.05),而临床疗效及2周真菌学清除率,两组差异无统计学意义(P>0.05);两组在临床疗效、症状及体征评分方面未见明显差异(P>0.05)。结论 1%卢立康唑乳膏治疗念珠菌性包皮龟头炎具有良好的疗效及安全性,值得临床推广。 Objective To investigate the curative efficiency and safety of luliconazole 1 ~ cream in treating candidal balano- posthitis.Methods A total of 70 outpatients from department of Dermatology & STD were randomly divided into two groups.Among them, 38 were given luliconazole 1% cream once a day (study group) while the others were given ketoconazole cream once a day (control group),The effect was evaluated based on scores of relief for symptoms,skin signs,and mycology inspection, while the safety was evaluated according to the side effects.Results The mycological clearance rate of 1% lulicon azole cream was significantly higher than that of 2% ketoconazole cream one week after treatment (P〈0.05),but there was no significant difference of clinical efficacy and mycological clearance rate between the two groups two weeks after treatment (P 〉0,05).No significant difference was observed between the two groups in evaluation scores of clinical effect, symptom and skin sign aspects.Conclusions The curative effect and safety for 1%luliconazole cream were comparable to those of 2% ketoconazole cream in treating candidal balanoposthitis.It is worth popularizing and applying clinically.
出处 《中国真菌学杂志》 CSCD 2016年第6期381-384,共4页 Chinese Journal of Mycology
基金 中国中西医结合临床研究基金(CAIM-LLKZ-002)
关键词 卢立康唑 念珠菌性包皮龟头炎 疗效观察 luliconazole candidal balanoposthitis curative effect
  • 相关文献

参考文献3

二级参考文献34

  • 1李军,郑和义,孙秋宁,闫岩.念珠菌性龟头炎及其致病菌种、药敏分析[J].临床皮肤科杂志,2004,33(7):398-400. 被引量:16
  • 2许良杰,黄进波,苏惜香,陈建宁,许敏鸿.念珠菌性包皮龟头炎的致病菌种及其药敏试验分析[J].中国皮肤性病学杂志,2007,21(3):167-168. 被引量:17
  • 3Koga H, Nanjoh Y, Makimura K, et al. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol, 2009, 47(6): 640-647.
  • 4Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis-comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses, 2007, 50( 1 ): 35-40.
  • 5Watanabe S, Takahashi H, Nishikawa T, et al. A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses, 2006, 49(3): 236-241.
  • 6Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard CLSI document M27-A3. Wayne, PA. 2008.
  • 7Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third Infor- mational Supplement. CLSI Document M27-$3. Wayne, PA, 2008.
  • 8Uehida K, Tanaka T, Yamaguchi H. Achievement of complete mycol- ogical cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis. Microbiol Immunol, 2003, 47(2): 143-146.
  • 9Niwano Y, Kuzuhara N, Goto Y, et al. Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida alblcans and Aspergillus fumlgatus infections. Int J Antimicrob Agents, 1999, 12(3): 221-228.
  • 10Uchida K, Nishiyama Y, Tanaka T, et al. In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. Int J Antimicrob Agents, 2003, 21(3): 234-238.

共引文献28

同被引文献53

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部